Baxter licks its wounds as it takes $293 million losses
This article was originally published in Clinica
Baxter Healthcare Corporation has decided to abandon and write off the expenditure on its blood substitute, HemAssist. At the same time it is making provisions for other misfortunes which have befallen the $6.1 billion company. The total provision in the third quarter will be $293 million.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.